Cardiol Therapeutics Inc.
CRDL.TO
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -24.20% | -17.43% | 31.04% | 48.15% | 66.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -16.41% | -7.86% | 23.08% | 28.79% | 33.21% |
| Operating Income | 16.41% | 7.86% | -23.08% | -28.79% | -33.21% |
| Income Before Tax | 9.62% | 6.33% | -24.60% | -15.00% | -28.61% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 9.62% | 6.33% | -24.60% | -15.00% | -28.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 9.62% | 6.33% | -24.60% | -15.00% | -28.61% |
| EBIT | 16.41% | 7.86% | -23.08% | -28.79% | -33.21% |
| EBITDA | 15.75% | 7.19% | -23.08% | -28.64% | -32.90% |
| EPS Basic | 25.53% | 22.99% | -7.15% | -1.05% | -16.80% |
| Normalized Basic EPS | 25.51% | 23.00% | -7.17% | -1.07% | -16.89% |
| EPS Diluted | 25.53% | 22.99% | -7.15% | -1.05% | -16.80% |
| Normalized Diluted EPS | 25.51% | 23.00% | -7.17% | -1.07% | -16.89% |
| Average Basic Shares Outstanding | 21.55% | 21.91% | 18.76% | 15.55% | 11.02% |
| Average Diluted Shares Outstanding | 21.55% | 21.91% | 18.76% | 15.55% | 11.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |